Latest liver transplant Stories
HORSHOLM, Denmark, March 3, 2015 /PRNewswire/ -- Veloxis Pharmaceuticals A/S (OMX: VELO) ('Veloxis') today published the annual report of Veloxis Pharmaceuticals A/S for the financial year 2014.
- In adult patients co-infected with genotype 1 (GT1) hepatitis C virus (HCV) infection and human immunodeficiency virus (HIV) type 1 infection, TURQUOISE-I demonstrated sustained virologic response
Data from 25 accepted abstracts include results from: NORTH CHICAGO, Ill., Oct.
Hospital successfully transplants the first liver dialysis patient in the state HOUSTON, July 11, 2014 /PRNewswire-USNewswire/ -- Texas Children's Hospital is excited to announce the
HORSHOLM, Denmark, May 22, 2014 /PRNewswire/ -- Veloxis Pharmaceuticals A/S (OMX: VELO) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency
- Study published online in Liver Transplantation - HORSHOLM, Denmark, April 28, 2014 /PRNewswire/ -- Veloxis Pharmaceuticals A/S (OMX: VELO) today announced the publication of a Phase II study
New research announced at the International Liver CongressTM 2014 today provides new hope for the notoriously difficult-to-treat population of liver transplant patients with recurring hepatitis C (HCV).
Veterans with liver disease who live more than 100 miles from a Veterans Administration hospital that offers liver transplants are only half as likely to be placed on the liver transplant waitlist to receive a new organ compared to veterans who live closer to transplant centers.
Hepatitis B Foundation honors liver transplant pioneer with highest scientific honor. Doylestown, PA (PRWEB) March 19, 2014 The Hepatitis B Foundation
Patients waiting for liver transplants who develop hepatopulmonary syndrome (HPS), a lung disorder associated with end-stage liver disease, are eligible to move up on the wait list.
- Growing in low tufty patches.